NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

Core Viewpoint - Investors have until July 22, 2025, to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for failing to disclose material information during the class period from November 3, 2022, to April 30, 2025 [1][3] Company Information - Organon & Co. is facing lawsuits for allegedly violating federal securities laws by not disclosing important information during the specified class period [3] - The company announced a significant reduction in its dividend payout from $0.28 to $0.02 on March 10, 2025, which contradicted previous assurances to investors about maintaining the dividend [4] Financial Impact - Following the announcement of the dividend cut, Organon's share price dropped over 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4] Legal Proceedings - The first filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322, with a subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanding the class period [5]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend policy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The complaint alleges that the defendants made overwhelmingly positive statements while concealing the high priority of debt reduction following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the revelations regarding the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5]. Group 3: Investor Outreach - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [6].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Allegations - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve a $1 billion milestone payment from Merck & Co. related to Nexplanon sales, nor maintain the required $1 billion in free cash flow to sustain its dividend [4]. - The lawsuit further asserts that the company might not maintain its corporate debt ratings and lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which led to a stock price drop of over 27% [5].

Core Viewpoint - Organon (OGN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of surpassing expectations in previous quarters [1][2]. Earnings Performance - Organon has consistently exceeded earnings estimates, with an average surprise of 9.63% over the last two quarters [2]. - In the most recent quarter, the expected earnings were $1.02 per share, but the actual reported earnings were $0.89 per share, resulting in a surprise of 14.61% [2]. - For the previous quarter, the consensus estimate was $0.86 per share, while the actual earnings were $0.90 per share, leading to a surprise of 4.65% [2]. Earnings Estimates and Predictions - Recent estimates for Organon have been revised upward, indicating growing analyst confidence in the company's near-term earnings potential [5]. - The Zacks Earnings ESP for Organon is currently +5.32%, suggesting a favorable outlook for an earnings beat [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) enhances the likelihood of another earnings surprise [8]. Statistical Insights - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions prior to earnings releases [7].

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that affected investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose risks related to Nexplanon sales growth, which impacted investor expectations and stock performance [1][3]. Summary by Sections Lawsuit Details - The lawsuit represents purchasers of Organon securities from November 3, 2022, to April 30, 2025, alleging that the company did not disclose a higher risk of loss of exclusivity and price erosion for Nexplanon [1][3]. Investor Information - Investors who acquired Organon securities during the class period have until July 22, 2025, to seek appointment as lead plaintiff [2]. Financial Impact - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [4]. - Following this announcement, Organon’s stock price fell by $3.48, approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors are encouraged to seek additional information and have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from November 3, 2022, to April 30, 2025, and the lead plaintiff deadline is July 22, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Allegations Against Organon - The lawsuit alleges that Organon made false or misleading statements regarding its product Nexplanon, including an overstated sales growth projection [4]. - It is claimed that Organon would not achieve the projected $1 billion in sales by the end of fiscal year 2025, nor the subsequent $1.5 billion [4]. - The lawsuit also suggests that Organon may not maintain the required $1 billion in free cash flow to sustain its dividend, nor its corporate debt ratings [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].